These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 38771472)

  • 21. Efficacy of SGLT2 Inhibitors as the Fifth Drug in the Management of Type 2 Diabetes Mellitus in Asian Indians not Controlled with at least 4 Oral Antidiabetic Drugs.
    Panikar V; Joshi SR; Deogaonkar N; Vadgama J; Nasikkar N; Kamat T; Sheikh S; Jain CC; Wagle T
    J Assoc Physicians India; 2018 Dec; 66(12):46-49. PubMed ID: 31315325
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The potential role of sodium glucose co-transporter 2 inhibitors in combination therapy for type 2 diabetes mellitus.
    Lajara R
    Expert Opin Pharmacother; 2014 Dec; 15(17):2565-85. PubMed ID: 25316597
    [TBL] [Abstract][Full Text] [Related]  

  • 23. SGLT2-inhibitors are effective and safe in the elderly: The SOLD study.
    Lunati ME; Cimino V; Gandolfi A; Trevisan M; Montefusco L; Pastore I; Pace C; Betella N; Favacchio G; Bulgheroni M; Bucciarelli L; Massari G; Mascardi C; Girelli A; Morpurgo PS; Folli F; Luzi L; Mirani M; Pintaudi B; Bertuzzi F; Berra C; Fiorina P
    Pharmacol Res; 2022 Sep; 183():106396. PubMed ID: 35970329
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes.
    Ferrannini E; Seman L; Seewaldt-Becker E; Hantel S; Pinnetti S; Woerle HJ
    Diabetes Obes Metab; 2013 Aug; 15(8):721-8. PubMed ID: 23398530
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rationale and design of the EMPA-ELDERLY trial: a randomised, double-blind, placebo-controlled, 52-week clinical trial of the efficacy and safety of the sodium-glucose cotransporter-2 inhibitor empagliflozin in elderly Japanese patients with type 2 diabetes.
    Yabe D; Shiki K; Suzaki K; Meinicke T; Kotobuki Y; Nishida K; Clark D; Yasui A; Seino Y
    BMJ Open; 2021 Apr; 11(4):e045844. PubMed ID: 33827843
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study.
    Heerspink HJL; Karasik A; Thuresson M; Melzer-Cohen C; Chodick G; Khunti K; Wilding JPH; Garcia Rodriguez LA; Cea-Soriano L; Kohsaka S; Nicolucci A; Lucisano G; Lin FJ; Wang CY; Wittbrodt E; Fenici P; Kosiborod M
    Lancet Diabetes Endocrinol; 2020 Jan; 8(1):27-35. PubMed ID: 31862149
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Benefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis.
    Storgaard H; Gluud LL; Bennett C; Grøndahl MF; Christensen MB; Knop FK; Vilsbøll T
    PLoS One; 2016; 11(11):e0166125. PubMed ID: 27835680
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term effectiveness and safety of quadruple combination therapy with empagliflozin versus dapagliflozin in patients with type 2 diabetes: 3-year prospective observational study.
    Ku EJ; Lee DH; Jeon HJ; Oh TK
    Diabetes Res Clin Pract; 2021 Dec; 182():109123. PubMed ID: 34740742
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High-dose sodium-glucose co-transporter-2 inhibitors are superior in type 2 diabetes: A meta-analysis of randomized clinical trials.
    Shi FH; Li H; Shen L; Fu JJ; Ma J; Gu ZC; Lin HW
    Diabetes Obes Metab; 2021 Sep; 23(9):2125-2136. PubMed ID: 34048142
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rationale, design and baseline characteristics of a 4-year (208-week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add-on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic control.
    Ridderstråle M; Svaerd R; Zeller C; Kim G; Woerle HJ; Broedl UC;
    Cardiovasc Diabetol; 2013 Sep; 12():129. PubMed ID: 24007456
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Can we go beyond surrogates?
    Drexler A
    J Diabetes; 2017 Nov; 9(11):976-977. PubMed ID: 28692750
    [TBL] [Abstract][Full Text] [Related]  

  • 32. SGLT2 Inhibitors: the Star in the Treatment of Type 2 Diabetes?
    Saisho Y
    Diseases; 2020 May; 8(2):. PubMed ID: 32403420
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Predictors of the Therapeutic Efficacy and Consideration of the Best Combination Therapy of Sodium-Glucose Co-transporter 2 Inhibitors.
    Lee JY; Cho Y; Lee M; Kim YJ; Lee YH; Lee BW; Cha BS; Kang ES
    Diabetes Metab J; 2019 Apr; 43(2):158-173. PubMed ID: 30688052
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rationale for the Early Use of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Type 2 Diabetes.
    Handelsman Y
    Adv Ther; 2019 Oct; 36(10):2567-2586. PubMed ID: 31444707
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Retrospective Observational Study on Assessing Sitagliptin and Dapagliflozin as a Fixed-Dose Combination in the Indian Population With Type 2 Diabetes Mellitus: The SIDAXA Study.
    Chawla M; Panneerselvam D; Gundgurthy A; Sud S; Alamchandani R; Aneja P; Nair R; Korukonda KR
    Cureus; 2024 May; 16(5):e60815. PubMed ID: 38910691
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A model-based meta analysis study of sodium glucose co-transporter-2 inhibitors.
    Yao X; Zhou J; Song L; Ren Y; Hu P; Liu D
    CPT Pharmacometrics Syst Pharmacol; 2023 Apr; 12(4):487-499. PubMed ID: 36890732
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predictors for the Treatment Effect of Sodium Glucose Co-transporter 2 Inhibitors in Patients with Type 2 Diabetes Mellitus.
    Yagi S; Aihara KI; Kondo T; Kurahashi K; Yoshida S; Endo I; Fukuda D; Nakaya Y; Suwaki KI; Takeji T; Wada T; Salim HM; Hama S; Matsuura T; Ise T; Kusunose K; Yamaguchi K; Tobiume T; Yamada H; Soeki T; Wakatsuki T; Matsuhisa M; Shimabukuro M; Akaike M; Sata M
    Adv Ther; 2018 Jan; 35(1):124-134. PubMed ID: 29185199
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of combination pioglitazone with sodium-glucose cotransporter-2 inhibitors or glucagon-like peptide-1 receptor agonists on outcomes in type 2 diabetes: A systematic review, meta-analysis, and real-world study from an international federated database.
    Anson M; Henney AE; Zhao SS; Ibarburu GH; Lip GYH; Cuthbertson DJ; Nabrdalik K; Alam U
    Diabetes Obes Metab; 2024 Jul; 26(7):2606-2623. PubMed ID: 38558280
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Incretin mimetics and sodium-glucose co-transporter 2 inhibitors as monotherapy or add-on to metformin for treatment of type 2 diabetes: a systematic review and network meta-analysis.
    Jia S; Wang Z; Han R; Zhang Z; Li Y; Qin X; Zhao M; Xiang R; Yang J
    Acta Diabetol; 2021 Jan; 58(1):5-18. PubMed ID: 32514989
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and efficiency of SGLT2 inhibitor combining with insulin in subjects with diabetes: Systematic review and meta-analysis of randomized controlled trials.
    Yang Y; Chen S; Pan H; Zou Y; Wang B; Wang G; Zhu H
    Medicine (Baltimore); 2017 May; 96(21):e6944. PubMed ID: 28538386
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.